EUCTR2011-001777-43-PL进行中（未招募）不适用
A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening over 12 weeks as add-on controller therapy on top of usual care in children (6 to 11 years old) with severe persistent asthma
Boehringer0 个研究点目标入组 375 人开始时间: 2014年5月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 375
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.All patients’ parent(s) (or legal guardian) must sign and date an informed consent prior to participation in the trial. In addition, an informed assent suitable for this age group has to be obtained from patients. A separate informed consent/assent is required for pharmacogenomic sampling.
- •2.Male or female patients between 6 and 11 years of age.
- •3.All patients must have at least a 6-month history of asthma.
- •4.All patients must have been on maintenance treatment with an inhaled corticosteroid either at stable high dose in combination with another controller medication, OR at stable medium dose in combination with two other controller medications, for at least 4 weeks before Visit 1.
- •5.All patients must be symptomatic (partly controlled) at Visit 1 and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ-IA) mean score >= 1.5.
- •6.All patients must have a pre-bronchodilator forced expiratory volume in one second (FEV1) >= 60% and <= 90% of predicted normal at Visit 1.
- •7.Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%) as compared to Visit 2 (pre-dose) must be within ± 30%.
- •8.All patients must confirm the diagnosis of asthma by bronchodilator reversibility at Visit 1, resulting in an increase in FEV1 of >= 12% 15 to 30 minutes after 200 mcg salbutamol/albuterol.
- •9.Patients must be able to use the Respimat inhaler correctly.
- •10.Patients must be able to perform all trial related procedures including technically acceptable pulmonary function tests and use of electronic diary/peak flow meter (diary compliance of at least 80% is required).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 375
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with a significant disease other than asthma.
- •2.Patients with a clinically relevant abnormal haematology or blood chemistry at screening.
- •3.Patients with a history of congenital or acquired heart disease, or patients who have been hospitalised for cardiac syncope or failure during the past year.
- •4.Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year.
- •5.Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years.
- •6.Patients with known active tuberculosis.
- •7.Patients who have undergone thoracotomy with pulmonary resection.
- •8.Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to Visit 1.
- •9.Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other components of the inhalation solution used with the Respimat inhaler.
- •10.Pregnant or nursing female patients, including postmenarchal girls with a positive urine pregnancy test at Visit 1.
- •11.Postmenarchal girls of child-bearing potential not using a highly effective method of birth control.
- •12.Patients who have been treated with systemic corticosteroids within four weeks prior to Visit 1.
- •13.Patients who have been treated with systemic beta-adrenergics within four weeks prior to Visit 1.
- •14.Patients who have been treated with oral beta-blocker medication within four weeks prior to Visit 1 and/or during the screening period.
- •15.Patients who have been treated with inhaled long-acting anticholinergics or systemic anticholinergic treatment within four weeks prior to Visit 1 and/or during the screening period, or who have been treated with inhaled short-acting anticholinergics within two weeks prior to Visit 1.
- •16.Patients who have been treated with short-acting theophylline preparations within two weeks prior to Visit 1.
- •17.Patients who have been treated with non-approved and according to international guidelines not recommended experimental drugs for routine asthma therapy within four weeks prior to Visit 1 and/or during the screening period.
- •18.Patients who have taken an investigational drug within six half lives according to the investigator’s information, or four weeks (whichever is greater) prior to Visit 1 and/or during the screening period.
- •19.Patients who have previously been randomised in this trial or are currently participating in another trial.
- •20.Patients with any acute asthma exacerbation or respiratory tract infection in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.
- •21.Patients requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.
- •22.Patients who are unable to comply with medication restrictions prior to Visit 1 and/or prior to Visit 2.
- •23.Patients with a known narrow-angle glaucoma, or any other disease where anticholinergic treatment is contraindicated.
- •24.Patients with moderate to severe renal impairment, as defin
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome. - NDRestless Legs SyndromeMedDRA version: 6.1Level: PTClassification code 10058920EUCTR2005-005372-32-ITGLAXO SMITHKLINE400
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen (as lysinate) lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAupper respiratory illness : sore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throatEUCTR2008-008265-36-FRSANOFI-AVENTIS GROUPE835
进行中（未招募）
1 期
The effect of Tiotropium+olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in patients with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004253-11-GBBoehringer Ingelheim Limited544
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAupper respiratory illness : sore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throatEUCTR2008-008265-36-FISANOFI-AVENTIS GROUPE835
进行中（未招募）
不适用
Efficacy and safety of 2 doses of Tiotropium Respimat compared to placebo in adolescents with severe persistent asthmapatients of either sex, 12 to 17 years old, with a diagnosis of severe persistent asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021778-13-DEBoehringer Ingelheim Pharma GmbH & Co. KG375